1. Home
  2. NRSN
  3. NRSN News

Latest NeuroSense Therapeutics Ltd. (NRSN) News on January 19, 2025

NRSN

MT Newswires

13 days ago

NeuroSense Therapeutics Regains Compliance With Nasdaq Equity Requirement

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NRSN

PR Newswire

13 days ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NRSN

MT Newswires

23 days ago

Neurosense Therapeutics Files for Resale of Up to 5.28 Million Shares

NRSN

MT Newswires

a month ago

NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
NRSN

PR Newswire

a month ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
NRSN

PR Newswire

a month ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
NRSN

PR Newswire

a month ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NRSN

MT Newswires

a month ago

NeuroSense Therapeutics Files Prospectus for Secondary Stock Sale

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
NRSN

PR Newswire

a month ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
NRSN

PR Newswire

2 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
NRSN

PR Newswire

2 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NRSN

MT Newswires

3 months ago

Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
NRSN

PR Newswire

3 months ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
NRSN

Benzinga

3 months ago

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
NRSN

PR Newswire

3 months ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
NRSN

PR Newswire

3 months ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NRSN

MT Newswires

3 months ago

NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NRSN

PR Newswire

3 months ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
NRSN

PR Newswire

3 months ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
NRSN

PR Newswire

4 months ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
NRSN

PR Newswire

4 months ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NRSN

PR Newswire

5 months ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
NRSN

Benzinga

5 months ago

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
NRSN

PR Newswire

5 months ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
NRSN

PR Newswire

6 months ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
NRSN

PR Newswire

6 months ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
NRSN

PR Newswire

7 months ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
NRSN

PR Newswire

7 months ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NRSN

MT Newswires

7 months ago

NeuroSense Therapeutics Receives Delisting Notice From Nasdaq

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
NRSN

PR Newswire

7 months ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Lotto 6/49 - $64 million up for grabs in the next draw!
NRSN

CNW Group

7 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
NRSN

Simply Wall St.

7 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
NRSN

AFP

7 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
NRSN

Simply Wall St.

7 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
NRSN

Simply Wall St.

7 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
NRSN

Barrons.com

7 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
NRSN

Simply Wall St.

7 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
NRSN

Simply Wall St.

7 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
NRSN

PR Newswire

8 months ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NRSN

MT Newswires

8 months ago

NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
NRSN

PR Newswire

8 months ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
NRSN

PR Newswire

8 months ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update
NRSN

PR Newswire

9 months ago

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NRSN

PR Newswire

9 months ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NRSN

PR Newswire

9 months ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NRSN

PR Newswire

9 months ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
NRSN

PR Newswire

9 months ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NRSN

PR Newswire

9 months ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
NRSN

PR Newswire

9 months ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
NRSN

PR Newswire

a year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
NRSN

PR Newswire

a year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS
NRSN

PR Newswire

a year ago

SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS

NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
NRSN

ACCESSWIRE

a year ago

NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

Edgio Names BDO as Independent Auditor
NRSN

Business Wire

a year ago

Edgio Names BDO as Independent Auditor

11 Hyper-Growth Stocks Billionaires Are Loading Up On
NRSN

Insider Monkey

a year ago

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
NRSN

GlobeNewswire

a year ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Sphere 3D Announces Agreement with Core Scientific
NRSN

Newsfile

a year ago

Sphere 3D Announces Agreement with Core Scientific

NRSN

GlobeNewswire

a year ago

GYRODYNE ANNOUNCES RECORD DATE FOR PROPOSED RIGHTS OFFERING

3 Stocks With the Best Shot to 10X by 2025
NRSN

InvestorPlace

a year ago

3 Stocks With the Best Shot to 10X by 2025

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10
NRSN

Simply Wall St.

a year ago

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
NRSN

PR Newswire

a year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

NRSN

Business Wire

a year ago

Owlet Transforms Infant Care with the Launch of Two FDA-Cleared Devices – Dream Sock® and BabySat™

Tuttle Capital Management Launches 2x Inverse Regional Bank ETF
NRSN

GlobeNewswire

a year ago

Tuttle Capital Management Launches 2x Inverse Regional Bank ETF

AppTech Payments Corp. to Attend Consumer Electronics Show in Las Vegas January 9-12, 2024
NRSN

GlobeNewswire

a year ago

AppTech Payments Corp. to Attend Consumer Electronics Show in Las Vegas January 9-12, 2024

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
NRSN

GlobeNewswire

a year ago

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

Li-Cycle Receives Continued Listing Standard Notice from NYSE
NRSN

Business Wire

a year ago

Li-Cycle Receives Continued Listing Standard Notice from NYSE

Davis Commodities Limited Announces First Half of Fiscal Year 2023 Unaudited Financial Results
NRSN

GlobeNewswire

a year ago

Davis Commodities Limited Announces First Half of Fiscal Year 2023 Unaudited Financial Results

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
NRSN

PR Newswire

a year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Can Mixed Fundamentals Have A Negative Impact on AstroNova, Inc. (NASDAQ:ALOT) Current Share Price Momentum?
NRSN

Simply Wall St.

a year ago

Can Mixed Fundamentals Have A Negative Impact on AstroNova, Inc. (NASDAQ:ALOT) Current Share Price Momentum?

We Think VirnetX Holding (NYSE:VHC) Needs To Drive Business Growth Carefully
NRSN

Simply Wall St.

a year ago

We Think VirnetX Holding (NYSE:VHC) Needs To Drive Business Growth Carefully

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
NRSN

PR Newswire

a year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

santec Leverages Rimini Consult™ to Comprehensively Restructure its SAP Systems in Support of Major Corporate Restructuring
NRSN

Business Wire

a year ago

santec Leverages Rimini Consult™ to Comprehensively Restructure its SAP Systems in Support of Major Corporate Restructuring

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)
NRSN

Simply Wall St.

a year ago

Many Still Looking Away From OceanPal Inc. (NASDAQ:OP)

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives
NRSN

Business Wire

a year ago

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives

We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
NRSN

Simply Wall St.

a year ago

We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
NRSN

PR Newswire

a year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NRSN

PR Newswire

a year ago

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Despite Fast-paced Momentum, Owlet, Inc. (OWLT) Is Still a Bargain Stock
NRSN

Zacks

a year ago

Despite Fast-paced Momentum, Owlet, Inc. (OWLT) Is Still a Bargain Stock

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
NRSN

PR Newswire

a year ago

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Insider Spends US$59k Buying More Shares In Crown Crafts
NRSN

Simply Wall St.

a year ago

Insider Spends US$59k Buying More Shares In Crown Crafts

President of Epsilon Energy Picks Up 13% More Stock
NRSN

Simply Wall St.

a year ago

President of Epsilon Energy Picks Up 13% More Stock

Alarum: NetNut Announces Grant of a United States Patent
NRSN

GlobeNewswire

a year ago

Alarum: NetNut Announces Grant of a United States Patent

The Glimpse Group Reports Q1 Fiscal Year 2024 Financial Results
NRSN

ACCESSWIRE

a year ago

The Glimpse Group Reports Q1 Fiscal Year 2024 Financial Results

Nortech Systems Incorporated (NASDAQ:NSYS) Q3 2023 Earnings Call Transcript
NRSN

Insider Monkey

a year ago

Nortech Systems Incorporated (NASDAQ:NSYS) Q3 2023 Earnings Call Transcript

NRSN

PR Newswire

a year ago

Willamette Valley Vineyards Announces Annual Cash Dividend for Series A Redeemable Preferred Stock

BGSF, Inc. Presenting at the 15th Annual Southwest IDEAS Investor Conference on November 15th in Dallas, TX
NRSN

Business Wire

a year ago

BGSF, Inc. Presenting at the 15th Annual Southwest IDEAS Investor Conference on November 15th in Dallas, TX

NRSN

Zacks Small Cap Research

a year ago

DYAI: Third Quarter Update

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
NRSN

GlobeNewswire

a year ago

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

NRSN

Associated Press Finance

a year ago

Priority Technology: Q3 Earnings Snapshot

NRSN

Business Wire

a year ago

Priority Technology Holdings, Inc. Announces Third Quarter 2023 Financial Results

NEW PACIFIC REPORTS FINANCIAL RESULTS FOR THE THREE MONTH ENDED SEPTEMBER 30, 2023
NRSN

CNW Group

a year ago

NEW PACIFIC REPORTS FINANCIAL RESULTS FOR THE THREE MONTH ENDED SEPTEMBER 30, 2023

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
NRSN

GlobeNewswire

a year ago

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

BK Technologies Receives $315,000 Purchase Order from the United States Department of Defense for the BKR 9000 Multiband Radio
NRSN

ACCESSWIRE

a year ago

BK Technologies Receives $315,000 Purchase Order from the United States Department of Defense for the BKR 9000 Multiband Radio

NRSN

Associated Press Finance

a year ago

Sangamo: Q3 Earnings Snapshot

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
NRSN

Business Wire

a year ago

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
NRSN

GlobeNewswire

a year ago

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device

Share on Social Networks: